GlassScriptPhysician profile
Minhaz Karim
NPI 1831154426
$4,296.86
in general payments reported to CMS, 2019-2025
34 companies · $928 in 2025
The $928 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $725 · 2020: $249 · 2021: $462 · 2022: $541 · 2023: $599 · 2024: $793 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,319.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $890.58 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $509.60 | 2022-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $368.27 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $342.98 | 2019-2025 | Gardasil 9, Gardasil, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $334.74 | 2019-2025 | Airsupra, Breztri |
| Sanofi-Aventis U.S. LLC | $300.90 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.90 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $233.20 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $224.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $150.47 | 2021-2025 | Freestyle Libre 3 |
| Harmony Biosciences LLC | $78.68 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $72.56 | 2019-2025 | Spravato |
| Corcept Therapeutics | $71.69 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $54.73 | 2019-2022 | |
| Eisai INC. | $31.92 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.04 | 2019-2024 | Xifaxan |
| Kyowa Kirin, INC. | $28.01 | 2023 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $27.68 | 2023 | |
| Sanofi Pasteur INC. | $25.04 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.91 | 2022 | |
| Dexcom, INC. | $21.20 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.44 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.60 | 2025 | Nuzyra |
| Xeris Pharmaceuticals, INC. | $16.54 | 2022 | |
| Biogen, INC. | $14.74 | 2025 | Skyclarys |
| Astellas Pharma US INC | $14.56 | 2019 | |
| Amarin Pharma, INC. | $14.49 | 2019 | |
| Medtronic, INC. | $14.07 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.06 | 2019 | |
| Hikma Pharmaceuticals USA | $13.63 | 2022 | |
| Allergan, INC. | $12.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.73 | 2023 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $11.56 | 2019 | |
| Therapeuticsmd, INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minhaz Karim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.